Latest by Myles Helfand
Missed opportunities to prescribe PrEP to at-risk people; long-term viral suppression reduces cancer risk; sexual health clinics and linkage to care; neurocognitive benefits of low-dose hydrocortisone therapy for women.
HIV self-testing vs. professional HIV testing; the most effective influenza vaccine strategies for people with HIV; how age can affect flu vaccine efficacy; early HIV treatment and CD4:CD8 ratio normalization.
How can science improve on its own miracle? This is the conundrum at the heart of an ongoing conversation in HIV medicine over the future of long-acting antiretroviral therapy, or LA-ART. The promise of LA-ART lies in the freedom it can potentially offe...
Happy days for thrice-weekly dosing; shortfalls in chronic opioid therapy monitoring; neurocognition, treatment initiation, and high CD4; the link between influenza virus shedding and CD4 count.
Housing, social support, and HIV transmissibility among people who use drugs; concerning hepatitis C incidence trends in France; frailty among people aging with HIV; untreated HIV and brain atrophy.
The rising tide of syphilis among Americans with HIV; first-line treatment with D/C/F/TAF; peculiar findings on cancer treatment rates; poor flu vaccine response among older people.
HPV vaccination and anal (vs. oral) HPV infection; single-tablet E/C/F/TDF vs. HIV-2; an HIV-positive infant’s “founder” virus; male circumcision and antiretroviral scale-up in Kenya.
Prevalence of non-AIDS comorbidities prior to HIV diagnosis; wealth and HIV treatment access amidst universal health care; the uncertain benefits of food supplementation; the results of universal hepatitis C treatment access.
Substance use rates among people with HIV; the continuing risk of PML; tenofovir gel efficacy and menopause; the cumulative cost of the global fight against HIV.